Long-acting injectable CAB+RPV maintains high virologic suppression in patients with HIV and obesity, showing comparable real-world efficacy.
In patients with HIV‑1 infection and virologic suppression, switching to an investigational regimen of doravirine plus ...
Independent clinical validation strengthens ABL’s leadership in the fast‑growing HIV drug‑resistance testing market ABL ...
In a recent study published in the journal PLOS Biology, researchers in France investigated the cellular function and antiviral role of human SAMD9L and its paralog SAMD9 (short for sterile alpha ...
The experimental HIV vaccine regimen exhibited an acceptable safety profile and elicited robust immune responses in 99% of trial participants from sub-Saharan Africa. Its ability to induce broad ...
A groundbreaking discovery reveals how HIV integrates its genetic material into human DNA, exposing a key viral vulnerability that could lead to new therapies and bring the world closer to a ...
Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results